Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta-derived mesenchymal stem cells or placental MSC secretome in hydrogel for resistant diabetic foot ulcers
IRCT20240513061768N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of placenta-derived mesenchymal stem cells in diabetic foot ulcer (DFU) (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Wound size reduction. Started May 2024; status: completed.
02
Drugs
placenta-derived mesenchymal stem cells
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on IRCT20240513061768N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240513061768N1.